TERAVOLT study identifies 7 factors associated with COVID-19 mortality in thoracic cancer
TERAVOLT study identifies 7 factors associated with COVID-19 mortality in thoracic cancer

TERAVOLT study identifies 7 factors associated with COVID-19 mortality in thoracic cancer

The TERAVOLT study identified 7 factors associated with an increased mortality risk in patients with thoracic malignancies who have received COVID-19.

Seven significant mortality determinations have been identified for patients with thoracic malignancies who have received COVID-19, according to results from the TERAVOLT study published in Journal of Thoracic Oncology.1

Poor ECOG performance status was most strongly associated with negative COVID-19 results (OR, 2.47; 95% CI, 1.87-3.26), with other factors including neutrophil count (OR, 2.46; 95% CI , 1.76-3.44), serum procalcitonine (OR, 2.37; 95% CI, 1.64-3.43), development of pneumonia (OR, 1.95; 95% CI, 1.48- 2.58), c-reactive protein (OR, 1.90; 95% CI, 1.43-2.51), tumor stage at COVID-19 diagnosis (OR, 1.97; 95% CI, 1.46- 2.66) and age (OR, 1.71; 95% CI, 1.29-2.26).

“Despite ongoing efforts, including immunization campaigns and increased capacity, SARS-CoV-2 will still affect the continuity of treatment of patients with cancer, at least to some extent. In contrast to the evolving scenario, we delivered a comprehensive and powerful forecasting system that can be a useful tool for clinicians. ” Alessio Cortellini, MD, a medical oncologist and clinical scientist from Imperial College London, said in a press release.2

A total of 1591 patients were enrolled in the database between March 2020 and April 2021, and 1491 were included in the analysis.

Laboratory-confirmed COVID-19 infection was identified in 1432 patients and 59 patients were diagnosed based on radiological or clinical findings. Investigators reported that 57.3% of patients were men, 72.2% were white, and 77.8% were former and current smokers. The median age of the patients was 67 years and 57.3% of the patients were 65 years or older.

Among the patients included in the study, most had 1 comorbidity (82.3%), such as hypertension (48.0%), chronic obstructive pulmonary disease (24.5%), diabetes (19.3%) and ischemic heart disease (13.1%). %). In addition, most patients concomitantly took non-cancer-related medication when they were diagnosed with COVID-19 (73.4%). Prior to the COVID-19 diagnosis, 13.0% of patients were on corticosteroids.

The most common tumor types were non-small cell lung cancer (79.7%), small cell lung cancer (12.4%) and other thoracic malignancies (7.9%). At the time of diagnosis of COVID-19, 67.8% of patients had stage IV disease, 71.9% had an ECOG performance status of 0 or 1, 64.5% had received antineoplastic treatment within 3 months of diagnosis, and 38.8% had chemotherapy alone.

Therapy for patients with COVID-19 included anticoagulants (37.2%), antibiotics (48.7%), antivirals (18.9%), antifungals (2.6%), corticosteroids (33.4%), interleukin-6 inhibitors (3.1%) and antimalarial drugs (16.4%). During the average observation period of 42 days, 361 incidents were reported, which translated into a death rate for all causes was 24.2%.

A total of 73 variables were considered in the cluster analysis, with significant correlations with results identified in 3 demographic, 5 comorbidity, 3 concomitant medication, 3 oncological features, 6 information on full blood count, 17 general biochemistry, 2 respiratory functions and 7 radiological find variables.

“Currently, this analysis did not look at the effect of COVD-19 vaccination. The TERAVOLT database has recently been updated to capture information on vaccination status, as well as information on the specific variants. A separate analysis will be performed with the new data. . ” Jennifer G. Whisenant, PhD, a research assistant professor of medicine at Vanderbilt University, concluded.

References

1. Whisenant J, Baena J, Cortellini A, et al. A definitive prognosis system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry. J Thorac Oncol. Published online February 1, 2022. doi: 10.1016 / j.jtho.2021.12.015

The TERAVOLT study identifies seven factors that increase the mortality risk for patients with COVID-19. News release. International Association for the Study of Lung Cancer. February 1, 2022. Visited February 1, 2022. https://bit.ly/3ANKRJh

Leave a Reply

Your email address will not be published.